The Pulmatrix stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average.
Full Answer
Where can I buy Pulmatrix stock?
Shares of PULM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Pulmatrix's stock price today?
What does it mean when Pulmatrix gains volume on falling prices?
Further fall is indicated until a new bottom pivot has been found. Pulmatrix gained volume on the last day, but on falling prices. In technical terms, this is called divergence and may be an early warning. In some cases, increasing volume on falling prices may be considered positive, but that is mainly in typical "sell-offs".
How did Pulmatrix's earnings compare to analysts' earnings estimates?
The biotechnology company earned $2.25 million during the quarter, compared to analysts' expectations of $1.53 million. Pulmatrix had a negative net margin of 213.74% and a negative trailing twelve-month return on equity of 54.76%.
What is the mailing address for Pulmatrix?
Pulmatrix's mailing address is 99 HAYDEN AVENUE SUITE 390, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-357-2333 or via email at rclarke@pulmatrix.com.
Is pulmatrix a good stock?
Pulmatrix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Will pulmatrix go up?
Pulmatrix Inc quote is equal to 5.030 USD at 2022-05-27. Based on our forecasts, a long-term increase is expected, the "PULM" stock price prognosis for 2027-05-21 is 8.570 USD. With a 5-year investment, the revenue is expected to be around +70.38%. Your current $100 investment may be up to $170.38 in 2027.
What happened to pulmatrix?
What Happened With PULM Stock. Pulmatrix stock has been in steady decline since 2014, having dropped nearly 100% in that time. The pharmaceutical company specializes in the treatment of obstructive pulmonary disease that attacks the lungs, as well as treatments for asthma and migraine headaches.
Is POAI stock a buy?
Predictive Oncology Inc (NASDAQ:POAI) The 2 analysts offering 12-month price forecasts for Predictive Oncology Inc have a median target of 5.00, with a high estimate of 5.00 and a low estimate of 5.00. The median estimate represents a +1,149.69% increase from the last price of 0.40.
What is a 1 to 20 reverse stock split?
As a result of the Reverse Stock Split, every 20 shares of the Company's common stock issued and outstanding will be automatically reclassified into one new share of common stock.
Is PULM stock a buy right now?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pulmatrix in the last twelve months. There are currently 1 buy rating for...
Will Pulmatrix's stock price go up in 2022?
1 Wall Street analysts have issued 1 year target prices for Pulmatrix's shares. Their forecasts range from $10.00 to $10.00. On average, they antic...
How has Pulmatrix's stock performed in 2022?
Pulmatrix's stock was trading at $8.76 at the beginning of 2022. Since then, PULM shares have decreased by 40.5% and is now trading at $5.21. View...
Are investors shorting Pulmatrix?
Pulmatrix saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 22,800 shares, a decrease of...
When is Pulmatrix's next earnings date?
Pulmatrix is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022. View our earnings forecast for Pulmatrix .
How were Pulmatrix's earnings last quarter?
Pulmatrix, Inc. (NASDAQ:PULM) released its earnings results on Tuesday, March, 29th. The biotechnology company reported ($2.43) EPS for the quarter...
When did Pulmatrix's stock split? How did Pulmatrix's stock split work?
Shares of Pulmatrix reverse split on Tuesday, March 1st 2022. The 1-20 reverse split was announced on Tuesday, March 1st 2022. The number of shares...
Who are Pulmatrix's key executives?
Pulmatrix's management team includes the following people: Mr. Teofilo David Raad MBA , Pres, CEO & Director (Age 52, Pay $713.51k) Dr. Alexande...
Who are some of Pulmatrix's key competitors?
Some companies that are related to Pulmatrix include Akari Therapeutics (AKTX) , Atreca (BCEL) , Mereo BioPharma Group (MREO) , Merrimack Pharm...
When Will Pulmatrix, Inc. (NASDAQ:PULM) Turn A Profit?
With the business potentially at an important milestone, we thought we'd take a closer look at Pulmatrix, Inc.'s...
Pulmatrix Issues Letter to Stockholders
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, issued the following letter to stockholders from Chief Executive Officer Ted Raad.
Is Pulmatrix stock a positive or negative stock?
There are few to no technical positive signals at the moment. The Pulmatrix stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $0.77 and $0.77. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Thursday, October 28, 2021, and so far it has fallen -31.01%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Pulmatrix gained volume on the last day, but on falling prices. In technical terms, this is called divergence and may be an early warning. In some cases, increasing volume on falling prices may be considered positive, but that is mainly in typical "sell-offs".
Is Pulmatrix oversold?
Pulmatrix is oversold on RSI14 (24). Some stocks may drop long and hard while being oversold on RSI before turning, which increases the general risk.
Is Pulmatrix stock A Buy?
Pulmatrix holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Hold/Accumulate to a Sell candidate.
Why are Analyst Ratings Important?
Analytical research by professionals can be extremely useful when making investment decisions in the stock market. Analysts are able to observe industries in detail and learn how geographical impacts can affect a company's balance sheet. This information allows investors to make decisions ahead of the curve.
What's Happening With Pulmatrix Inc Stock Today?
Pulmatrix Inc (PULM) stock is higher by 4.41% while the S&P 500 is down -0.46% as of 10:44 AM on Tuesday, Feb 1. PULM has gained $0.02 from the previous closing price of $0.39 on volume of 204,096 shares. Over the past year the S&P 500 has gained 19.10% while PULM is down -72.11%. PULM lost -$0.38 per share the over the last 12 months.
Pulmatrix (PULM)
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Pulmatrix, Inc. - Hold
Zacks' proprietary data indicates that Pulmatrix, Inc. is currently rated as a Zacks Rank 3 and we are expecting an inline return from the PULM shares relative to the market in the next few months. In addition, Pulmatrix, Inc.
Style Scorecard
The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.
Chart for PULM
Pulmatrix, Inc. is a biopharmaceutical company which is engaged in developing inhaled therapies for serious pulmonary disease. The Company's proprietary product pipeline includes PUR1900, an inhaled anti-fungal for cystic fibrosis, PUR0200, a branded generic for chronic obstructive pulmonary disease which are in different clinical stage.